GLPwatch

Rybelsus vs Zepbound

Drug comparison

Last updated 2026-05-28 15:46 UTC

Rybelsus is an oral medication containing semaglutide, made by Novo Nordisk, and is FDA-approved to treat type 2 diabetes. Zepbound, made by Eli Lilly, contains tirzepatide and is given as a subcutaneous injection, FDA-approved for obesity and obstructive sleep apnea.

AI summary of the sources below.

Rybelsus Zepbound
Active ingredientsemaglutidetirzepatide
Manufacturernovo-nordiskeli-lilly
Routeoralsubcutaneous injection
FDA-approved fortype 2 diabetesobesity, obstructive sleep apnea
Label updated2026-01-302026-04-22

Compare full details on the Rybelsus and Zepbound pages.